Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 48

1.

Dropout rates in randomised antipsychotic drug trials.

Wahlbeck K, Tuunainen A, Ahokas A, Leucht S.

Psychopharmacology (Berl). 2001 May;155(3):230-3.

PMID:
11432684
2.

Randomised controlled trials of conventional antipsychotic versus new atypical drugs, and new atypical drugs versus clozapine, in people with schizophrenia responding poorly to, or intolerant of, current drug treatment.

Lewis SW, Davies L, Jones PB, Barnes TR, Murray RM, Kerwin R, Taylor D, Hayhurst KP, Markwick A, Lloyd H, Dunn G.

Health Technol Assess. 2006 May;10(17):iii-iv, ix-xi, 1-165.

3.

Dropout rates in placebo-controlled and active-control clinical trials of antipsychotic drugs: a meta-analysis.

Kemmler G, Hummer M, Widschwendter C, Fleischhacker WW.

Arch Gen Psychiatry. 2005 Dec;62(12):1305-12.

PMID:
16330718
4.

Control group bias in randomized atypical antipsychotic medication trials for schizophrenia.

Woods SW, Gueorguieva RV, Baker CB, Makuch RW.

Arch Gen Psychiatry. 2005 Sep;62(9):961-70. Review.

PMID:
16143728
5.

Effectiveness and cost of atypical versus typical antipsychotic treatment for schizophrenia in routine care.

Stargardt T, Weinbrenner S, Busse R, Juckel G, Gericke CA.

J Ment Health Policy Econ. 2008 Jun;11(2):89-97.

PMID:
18509216
6.

Meta-analysis of drop-out rates in randomised clinical trials, comparing typical and atypical antipsychotics in the treatment of schizophrenia.

Martin JL, Pérez V, Sacristán M, Rodríguez-Artalejo F, Martínez C, Alvarez E.

Eur Psychiatry. 2006 Jan;21(1):11-20. Epub 2005 Dec 27. Review.

PMID:
16380237
7.
8.

One-year clinical and economic consequences of oral atypical antipsychotics in the treatment of schizophrenia.

Edwards NC, Pesa J, Meletiche DM, Engelhart L, Thompson AK, Sherr J, Dirani R.

Curr Med Res Opin. 2008 Dec;24(12):3341-55. doi: 10.1185/03007990802490512 . Review.

PMID:
18954497
9.

The expert consensus guideline series. Optimizing pharmacologic treatment of psychotic disorders. Introduction: methods, commentary, and summary.

Kane JM, Leucht S, Carpenter D, Docherty JP; Expert Consensus Panel for Optimizing Pharmacologic Treatment of Psychotic Disorders.

J Clin Psychiatry. 2003;64 Suppl 12:5-19.

10.

Review of the efficacy of placebo in comparative clinical trials between typical and atypical antipsychotics.

Oliveira IR, Nunes PM, Coutinho DM, Sena EP.

Rev Bras Psiquiatr. 2009 Mar;31(1):52-6. Review.

11.

Lithium for schizophrenia revisited: a systematic review and meta-analysis of randomized controlled trials.

Leucht S, Kissling W, McGrath J.

J Clin Psychiatry. 2004 Feb;65(2):177-86. Review.

PMID:
15003070
12.

Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.

Plosker GL, Figgitt DP.

Pharmacoeconomics. 2004;22(6):389-411. Review.

PMID:
15099124
13.

Influence of methodology on outcomes of randomised clozapine trials.

Wahlbeck K, Tuunainen A, Gilbody S, Adams CE.

Pharmacopsychiatry. 2000 Mar;33(2):54-9.

PMID:
10761820
14.
15.

Dropout rates in randomized clinical trials of antipsychotics: a meta-analysis comparing first- and second-generation drugs and an examination of the role of trial design features.

Rabinowitz J, Levine SZ, Barkai O, Davidov O.

Schizophr Bull. 2009 Jul;35(4):775-88. doi: 10.1093/schbul/sbn005. Epub 2008 Feb 26.

16.

Atypical antipsychotics in the treatment of mania: a meta-analysis of randomized, placebo-controlled trials.

Perlis RH, Welge JA, Vornik LA, Hirschfeld RM, Keck PE Jr.

J Clin Psychiatry. 2006 Apr;67(4):509-16. Review.

PMID:
16669715
17.

Selection of atypical antipsychotics for the management of schizophrenia.

Sprague DA, Loewen PS, Raymond CB.

Ann Pharmacother. 2004 Feb;38(2):313-9. Epub 2003 Dec 30. Review.

PMID:
14742771
18.

Intravenous magnesium sulphate and sotalol for prevention of atrial fibrillation after coronary artery bypass surgery: a systematic review and economic evaluation.

Shepherd J, Jones J, Frampton GK, Tanajewski L, Turner D, Price A.

Health Technol Assess. 2008 Jun;12(28):iii-iv, ix-95. Review.

19.
20.

Supplemental Content

Support Center